A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPD

Trial Profile

A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPD

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Umeclidinium (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Apr 2015 Status changed from active, no longer recruiting to completed,as reported by ClinicalTrials.gov.
    • 22 Dec 2014 Planned End Date changed from 1 Apr 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
    • 22 Dec 2014 Planned primary completion date changed from 1 Apr 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top